Cardiac Angiogenic Gene Therapy Finding New Ways To Heal
Main Content
Clinical Trial
The Phase 3 “AFFIRM” clinical study evaluates Gene Biotherapeutics’ lead product candidate, Generx [Ad5FGF-4], as a one-time administration for the treatment of refractory angina due to late-stage coronary artery disease.
Our Science
Gene Biotherapeutics’ angiogenic gene therapy is designed to improve cardiac perfusion (blood flow) and to increase the supply of oxygenated blood by promoting the growth of microvasculature in ischemic cardiac tissue.
Generx Product Candidate
Generx [Ad5FGF-4] is engineered to express secreted human fibroblast growth factor-4 (FGF-4) protein, a key regulator of angiogenesis. Generx is administered by an interventional cardiologist during a brief procedure similar to a diagnostic angiogram.
Take a moment to answer these few simple questions to see if you're a candidate for the clinical study.
Do you experience chest pain (angina) due to heart disease?
Do you take anti-anginal medication (e.g. nitroglycerin, beta blocker, ACE inhibitors?)?
Have you ever been prescribed Ranexa?
Do you still experience angina despite taking medication?
Does angina limit your physical activity and quality of life?
Have you had a bypass surgery or stent procedure and continue to have angina?
Do you have more than 3 angina attacks a week?
If you answered Yes to any of these questions, please visit myrefractoryangina.com to learn more about our Phase 3 AFFIRM Clinical Study
Visit Now
